In other recent news, Biogen has been the focus of several analyst updates and strategic developments. The company reported first-quarter 2025 revenues of $2.43 billion and an adjusted earnings per share of $3.02, surpassing both Canaccord Genuity's and consensus estimates. Despite this strong financial performance, Canaccord lowered its price target for Biogen to $220, maintaining a Buy rating, as analysts adjust expectations amid competitive pressures. H.C. Wainwright also maintained a Buy rating but reduced its price target to $187, citing a shift in neurologists' attitudes towards Biogen's Alzheimer's drug, Leqembi. Goldman Sachs reaffirmed its Buy rating with a $196 price target, noting Eisai's stronger-than-expected sales for Leqembi, though projecting a cautious outlook for future sales.